Atea Pharmaceuticals, Inc.
AVIR
$6.00
$0.091.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 125.03% | 88.41% | 39.40% | -42.48% | 21.96% |
| Gross Profit | -125.03% | -88.41% | -39.40% | 42.48% | -21.96% |
| SG&A Expenses | -46.72% | -34.62% | -25.78% | -22.68% | 15.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.56% | 45.05% | 16.92% | -44.07% | 19.52% |
| Operating Income | -58.56% | -45.05% | -16.92% | 44.07% | -19.52% |
| Income Before Tax | -54.98% | -35.34% | 8.25% | 45.87% | 14.16% |
| Income Tax Expenses | -3,108.00% | -13.27% | -14.81% | -12.12% | -35.53% |
| Earnings from Continuing Operations | -33.76% | -34.98% | 8.29% | 45.75% | 14.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.76% | -34.98% | 8.29% | 45.75% | 14.35% |
| EBIT | -58.56% | -45.05% | -16.92% | 44.07% | -19.52% |
| EBITDA | -58.74% | -45.20% | -16.97% | 44.14% | -19.59% |
| EPS Basic | -44.62% | -44.15% | 7.75% | 46.55% | 15.40% |
| Normalized Basic EPS | -93.01% | -77.90% | -29.40% | 46.67% | -34.70% |
| EPS Diluted | -44.62% | -44.15% | 7.75% | 46.55% | 15.40% |
| Normalized Diluted EPS | -93.01% | -77.90% | -29.40% | 46.67% | -34.70% |
| Average Basic Shares Outstanding | -7.50% | -6.36% | -0.60% | 1.48% | 1.23% |
| Average Diluted Shares Outstanding | -7.50% | -6.36% | -0.60% | 1.48% | 1.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |